Stocks and Investing
Stocks and Investing
Wed, August 3, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Berens Maintained (BPMC) at Hold with Increased Target to $65 on, Aug 3rd, 2022
Andrew Berens of SVB Leerink, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Increased Target from $56 to $65 on, Aug 3rd, 2022.
Andrew has made no other calls on BPMC in the last 4 months.
There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
- Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022
These are the ratings of the 4 analyists that currently disagree with Andrew
- Matthew Biegler of "Oppenheimer" Initiated at Buy and Held Target at $80 on, Friday, July 8th, 2022
- Derek Archila of "Wells Fargo" Initiated at Sell and Held Target at $40 on, Monday, June 27th, 2022
- David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
- Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
Contributing Sources